<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873050</url>
  </required_header>
  <id_info>
    <org_study_id>RP-21-010</org_study_id>
    <nct_id>NCT04873050</nct_id>
  </id_info>
  <brief_title>Treatment to Regress to Normoglycemia in Women With a Recent History of GDM</brief_title>
  <acronym>SWEET</acronym>
  <official_title>A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn With a Recent History of Gestational diabETes Mellitus: The SWEET Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid&#xD;
      recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia;&#xD;
      thereby filling a gap in efficacious pharmacologic intervention options for clinicians to&#xD;
      support postpartum diabetes recovery and reduce future risk of T2DM in young women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis of gestational diabetes mellitus (GDM) during pregnancy identifies young women&#xD;
      with abnormalities in pancreatic beta cell function that worsen over time, leading to&#xD;
      diabetes. It is estimated that between 15% and 70% of women with a history GDM will progress&#xD;
      to type 2 diabetes mellitus (T2DM). However, upon an impaired glucose tolerance test result&#xD;
      in the early postpartum period, the American College of Obstetricians and Gynecologists only&#xD;
      recommend considering referral for management, weight loss and physical activity counseling,&#xD;
      considering metformin if testing results are severe enough, and yearly assessment of glycemic&#xD;
      status. In many cases, it is possible to reverse diabetes by losing weight in the early&#xD;
      stages before permanent, systemic damage occurs. Therefore, there is a dire need for&#xD;
      efficacious pharmacologic intervention options in this period of postpartum diabetes recovery&#xD;
      to return women to normoglycemia and lower future T2DM risk. Weight loss and medications that&#xD;
      mitigate impairments in insulin secretion show the best promise for delaying or preventing&#xD;
      T2DM, the dominant form of diabetes that develops after GDM. The primary study objective is&#xD;
      &quot;to examine the efficacy of semaglutide 1mg compared to placebo on regression to&#xD;
      normoglycemia in women with dysglycemia and a recent history of gestational diabetes mellitus&#xD;
      (i.e., 6-36 months postpartum)&quot; to answer the research question of: &quot;Among women with&#xD;
      dysglycemia and a recent history of gestational diabetes mellitus, can acute treatment of&#xD;
      semaglutide 1mg lead to regression to normoglycemia?&quot;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression to normoglycemia</measure>
    <time_frame>After 24 weeks of full-dose treatment</time_frame>
    <description>Glucose tolerance to be determined by glycemic response to a 75 gram, two-hour oral glucose tolerance test (OGTT). Regression to normoglycemia is defined by fasting glucose &lt;100mg/dL and 120 minute glucose &lt;140 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>After 24 weeks of full-dose treatment</time_frame>
    <description>Hemoglobin to be determined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>After 24 weeks of full-dose treatment</time_frame>
    <description>Fasted body weight after intervention minus fasted body weight at enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Pre Diabetes</condition>
  <condition>Postpartum Disorder</condition>
  <arm_group>
    <arm_group_label>Semaglutide Pen Injector (Ozempic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly injections of semaglutide for 8 months total (2 months of titration; 6 months of full dose- 1mg/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Weekly injections of placebo for 8 months total</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide Pen Injector [Ozempic]</intervention_name>
    <description>Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses</description>
    <arm_group_label>Semaglutide Pen Injector (Ozempic)</arm_group_label>
    <other_name>Semaglutide 1mg</other_name>
    <other_name>Ozempic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo semaglutide pen injector</intervention_name>
    <description>Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Semaglutide 1mg</other_name>
    <other_name>Placebo Ozempic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female&#xD;
&#xD;
          2. 18 - 45 years old (inclusive)&#xD;
&#xD;
          3. History of gestational diabetes in most recent pregnancy&#xD;
&#xD;
          4. 6 - 36 months postpartum&#xD;
&#xD;
          5. BMI ≥ 25 kg/m2&#xD;
&#xD;
          6. Use of long-acting reversible contraception or bilateral tubal ligation&#xD;
&#xD;
          7. Dysglycemia as determined by glycemic response to 75g, 2-hour OGTT: either impaired&#xD;
             fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT):&#xD;
&#xD;
               1. Fasting glucose 100-125mg/dL (inclusive) and/or&#xD;
&#xD;
               2. 120 minute glucose 140-199mg/dL (inclusive)&#xD;
&#xD;
          8. Willingness to maintain physical activity level throughout study duration&#xD;
&#xD;
          9. Willingness to standardize diet for 3 days prior to OGTT&#xD;
&#xD;
         10. Ability to provide informed consent before any trial-related activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body weight &gt; 350lb&#xD;
&#xD;
          2. Pregnant or the intention of becoming pregnant or not using adequate contraceptive&#xD;
             measures.&#xD;
&#xD;
          3. Breastfeeding within 3 months of screening visit 1&#xD;
&#xD;
          4. Post-menopausal&#xD;
&#xD;
          5. Desiring pregnancy within study participation period or two months after participation&#xD;
             ends (i.e. 10 months from enrolment)&#xD;
&#xD;
          6. Use of tobacco products within past 6 months&#xD;
&#xD;
          7. Substance or alcohol abuse&#xD;
&#xD;
          8. Presence of significant systemic disease including: diabetes mellitus (type 1 or type&#xD;
             2), cardiac disease (e.g. congestive heart failure), renal impairment (e.g. serum&#xD;
             creatinine levels ≥ 1.4 mg/dL or eGFR &lt; 60), hepatic disease (including viral&#xD;
             hepatitis, toxic hepatic damage, jaundice of unknown aetiology, or abnormal liver&#xD;
             function tests), pancreatitis, uncontrolled thyroid disease (e.g. documented abnormal&#xD;
             TSH), adrenal disease (including Cushing's syndrome, congenital adrenal hyperplasia),&#xD;
             hyperlipidemia (fasting triglycerides &gt; 399mg%), untreated or poorly controlled&#xD;
             hypertension (resting blood pressure &gt;159/94 mmHg)&#xD;
&#xD;
          9. History of or presence of: eating disorder, malignant disease requiring chemotherapy,&#xD;
             or debilitating psychiatric disorder such as psychosis or neurological condition that&#xD;
             could confound outcome variables&#xD;
&#xD;
         10. History of bariatric surgery&#xD;
&#xD;
         11. Use of medications for glucose regulation: insulin (e.g. Humalog, Novolog, Humulin),&#xD;
             pramlintide, metiglinides, metformin, thiazolidinediones, GLP-1 receptor agonists,&#xD;
             DPP-4 inhibitors, SGLT2 inhibitors within four weeks of screening visit 1&#xD;
&#xD;
         12. Use of medications for anti-obesity or weight loss within four weeks of screening&#xD;
             visit 1&#xD;
&#xD;
         13. Use of medications known to exacerbate glucose dysfunction (such as isotretinoin or&#xD;
             corticosteroids) within four weeks of screening visit 1&#xD;
&#xD;
         14. Known or suspected allergy to trial medication, excipients, or related products&#xD;
&#xD;
         15. Contraindications to study medications: patients with a personal or family history of&#xD;
             medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome&#xD;
             type 2 (MEN 2)&#xD;
&#xD;
         16. Current or recent past (within 3 months) participation in another experimental drug&#xD;
             trial&#xD;
&#xD;
         17. Previous randomization in this trial&#xD;
&#xD;
         18. Receipt of any investigational drug within 6 months prior to this trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Sutton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Shaler, BS</last_name>
    <phone>225-231-5268</phone>
    <email>Donna.Shaler@womans.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Elkind-Hirsch, PhD</last_name>
    <phone>2259245278</phone>
    <email>karen.elkind-hirsch@womans.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70817</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Sutton, PhD</last_name>
      <phone>225-924-8446</phone>
      <email>elizabeth.sutton@womans.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Elizabeth F Sutton, PhD</investigator_full_name>
    <investigator_title>Director of Scientific Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puerperal Disorders</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

